329210-07-3

Basic information

• Product Name: ethyl 3-aMino-5-chloro-1-benzofuran-2-carboxylate
• Synonyms: ethyl 3-aMino-5-chloro-1-benzofuran-2-carboxylate
• CAS NO: 329210-07-3
• Molecular Formula: C11H10ClNO3
• Molecular Weight: 239.655
• Mol File: 329210-07-3.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: ethyl 3-aMino-5-chloro-1-benzofuran-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 3-aMino-5-chloro-1-benzofuran-2-carboxylate(329210-07-3)
• EPA Substance Registry System: ethyl 3-aMino-5-chloro-1-benzofuran-2-carboxylate(329210-07-3)

Safety Data

• Hazardous Substances Data: 329210-07-3(Hazardous Substances Data)

Usage

General Description

Ethyl 3-amino-5-chloro-1-benzofuran-2-carboxylate is a chemical compound with the molecular formula C12H10ClNO3. It is a benzofuran derivative and contains an ethyl ester group. ethyl 3-aMino-5-chloro-1-benzofuran-2-carboxylate has potential applications in the pharmaceutical industry, as it may have biological activity and therapeutic properties. It is important to handle and use this chemical with caution, following proper safety and handling protocols to prevent any potential hazards. Additionally, its properties and potential uses make it a subject of interest for further research and development in the field of medicinal chemistry.

Upstream product

• 13589-72-5 5-chloro-2-hydroxybenzonitrile 
• 401631-70-7 (4-chloro-2-cyano-phenoxy)-acetic acid ethyl ester 

Downstream Products

• 328277-09-4 8-Chloro-3H-benzo[4,5]furo[3,2-d]pyrimidin-4-one 
• 894796-29-3 3-amino-5-chlorobenzofuran-2-carboxylic acid 

Relevant articles and documents

Tricyclic aminopyrimidine histamine H4 receptor antagonists

This report discloses the development of a series of tricyclic histamine H4 receptor antagonists. Starting with a low nanomolar benzofuranopyrimidine HTS hit devoid of pharmaceutically acceptable properties, we navigated issues with metabolism and solubility to furnish a potent, stable and water soluble tricyclic histamine H4 receptor antagonist with desirable physiochemical parameters which demonstrated efficacy a mouse ova model.

Identification and hit-to-lead exploration of a novel series of histamine H4 receptor inverse agonists

The identification and hit-to-lead exploration of a novel, potent and selective series of histamine H4 receptor inverse agonists is described. The initial hit, 3A (IC50 19 nM) was identified by means of a ligand-based virtual screening approach. Subsequent medicinal chemistry exploration yielded 18I which possessed increased potency (R-enantiomer IC50 1 nM) as well as enhanced microsomal stability.

Pyrimidine compounds as histamine modulators

The present invention relates to novel pyrimidine compounds, for the modulation of the histamine H4 receptor and the treatment or prevention of conditions mediated by the histamine H4 receptor. The invention also relates to the preparation of such compoun